New York Workshop23–24 May, 1998 The influence of tissular cross-talking on osteoarthritis progression: role of nonsteroidal antiinflammatory drugs by unknown
Osteoarthritis and Cartilage (1999) 7, 301–302
? 1999 OsteoArthritis Research Society International 1063–4584/99/030301+02 $12.00/0
Article No. joca.1998.0172, available online at http://www.idealibrary.com onNew York Workshop
23–24 May, 1998
The influence of tissular cross-talking on osteoarthritis progression:
role of nonsteroidal antiinflammatory drugs
Sponsored by an unrestricted grant of UCB Pharma, Almirall Prodesfarma and Bristol Myers Squibb
Introduction J-P Pelletier and J-Y Reginster 306
Session I: Cartilage metabolism and osteoarthritis progression
Catabolic events in osteoarthritic cartilage F Blanco Garcia 308
Anabolic events in osteoarthritis Y Henrotin and J-Y Reginster 310
The e#ect of nonsteroidal antiinflammatory
drugs on human articular cartilage
glycosaminoglycan synthesis
JT Dingle 313
Session II: Synovial inflammation and osteoarthritis progression
Proinflammatory mediators and OA J Martel-Pelletier 315
Anticytokines S Gay, KM Hummel, T Pap, RE Gay 317
Synovial inflammation and osteoarthritis
progression: e#ects of nonsteroidal
antiinflammatory drugs
M Doherty 319
Session III: Subchondral bone and osteoarthritis progression
Subchondral bone morphological and
biochemical alterations in osteoarthritis
D Lajeunese, G Hilal, J-P Pelletier,
J Martel-Pelletier
321
Bone remodeling in OA: subchondral and
osteophytic responses
R Moskowitz 323
Subchondral bone should be the main target
for the treatment of pain and disease
progression in OA
P Dieppe 325
Carprofen reduces the structural changes and
the abnormal subchondral bone metabolism
of experimental osteoarthritis
J-P Pelletier, D Lajeunesse, G Hilal,
D Jovanovic, JC Fernandes,
J Martel-Pelletier
327
New Potential therapeutic goals: subchondral
bone and progression of osteoarthritis
J-P Mattei, H Roux 329
Bone saloprotein: a new marker for
subchondral bone
FA Wollheim 331301
302 New York WorkshopSession IV: Osteophytes and osteoarthritis progression
Osteophyte formation in osteoarthritis W van den Berg 333
Osteophytes in osteoarthritis K Brandt 334
Osteophytes and osteoarthritis progression:
e#ects of nonsteroidal antiinflammatory
drugs
J-P Devogelaere, DH Maincourt 336
Session V: Evaluation of disease progression during nonsteroidal antiinflammatory drug
treatment
Molecular markers of metabolic changes in
osteoarthritis
E Thonar 338








Evaluation of disease progression during
nonsteroidal antiinflammatory drugs imaging
by arthroscopy
M Dougados 345
Clinical trials: impact of intraarticular
steroid injections on the progression of knee
osteoarthritis
J-P Raynauld 348
Is there preliminary in-vivo evidences of an
influence of nonsteroidal antiinflammatory
drug treatment on osteoarthritis progression?
Part I
MG Lequesne 350
Is there preliminary in-vivo evidences of an
influence of nonsteroidal antiinflammatory
drug treatment on osteoarthritis progression?
Part II
U Serni, A Mannoni, M Benucci 351
Session VI: Osteoarthritis pathophysiology and nonsteroidal antiinflammatory drug treatment
Pathophysiological targets in OA therapy J-P Pelletier 353
In-vitro di#erences among nonsteroidal
antiinflammatory drugs in their activities
related to osteoarthritis pathophysiology
Y Henrotin, J-Y Reginster 355
